CORCEPT THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
Insider Trading Arrangements
During the quarter ended September 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, other than as set forth in the table below.
| Name | Position | Action | Adoption Date | Total Shares of Common Stock to be Sold | Expiration Date(1) |
|---|---|---|---|---|---|
| Daniel Swisher | Director | Adoption | 8/1/2024 | Up to 26,400 | 10/13/2025 |
| Joseph D. Lyon | Chief Accounting and Technology Officer | Adoption | 8/30/2024 | Up to 260,000 | 12/31/2025 |
| Sean Maduck | President, Endocrinology | Adoption | 9/5/2024 | Up to 340,000 | 12/31/2025 |
(1) Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.